{
    "clinical_study": {
        "@rank": "119553", 
        "brief_summary": {
            "textblock": "To characterize the pharmacokinetics of orally administered 3'-deoxy-3'-fluorothymidine\n      (FLT), in a liquid formulation, after single doses in asymptomatic HIV-infected patients and\n      to assess the safety and tolerance of the single oral doses of FLT."
        }, 
        "brief_title": "An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Oral candida infection documented by morphology or by response to antifungal therapy\n             within 2 months prior to study entry.\n\n          -  Temperature > 37.8 degrees Centigrade.\n\n          -  Malignancy other than cutaneous basal cell carcinoma or cervical carcinoma in situ.\n\n          -  Significant chronic underlying medical illnesses which would prevent continuous\n             participation in this clinical trial.\n\n        Concurrent Medication:\n\n        Excluded:\n\n        -\n\n        Patients with the following are excluded:\n\n          -  Significant chronic underlying medical illnesses which would prevent continuous\n             participation in this clinical trial.\n\n          -  Unwilling to sign informed consent.\n\n          -  Intolerant to zidovudine (AZT).\n\n          -  Oral hairy leukoplakia at any time prior to study entry.\n\n        Prior Medication:\n\n        Excluded within 7 days of study entry:\n\n          -  Antiretroviral drugs.\n\n          -  Immunomodulators.\n\n          -  Excluded within 30 days of study entry:\n\n          -  Any investigational drugs.\n\n        Patients have the following:\n\n          -  HIV seropositivity by licensed ELISA test, confirmed by Western Blot analysis.\n\n          -  No symptoms as defined by:\n\n               1. Normal neurological exam.\n\n               2. Absence of the following:\n\n          -  Unintentional weight loss of greater than 10 pounds or more than 10 percent of usual\n             body weight within 2 months prior to study entry.\n\n          -  Unexplained temperature > 37.8 C on more than 5 consecutive days or on more than 10\n             days in any 30 day period in the one month prior to expected study entry.\n\n          -  Unexplained diarrhea defined by = or > 3 liquid stools per day persisting > 7 days\n             within 2 months prior to expected study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002271", 
            "org_study_id": "054A", 
            "secondary_id": "81-1"
        }, 
        "intervention": {
            "intervention_name": "Alovudine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Alovudine", 
                "Dideoxynucleosides"
            ]
        }, 
        "keyword": [
            "Thymidine", 
            "Nucleosides", 
            "Antiviral Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21205"
                }, 
                "name": "Johns Hopkins Hosp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002271"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lederle Laboratories", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1991"
    }, 
    "geocoordinates": {
        "Johns Hopkins Hosp": "39.29 -76.612"
    }
}